The vaccine space is heating up in Malaysia as more non-core company’s look into having a pie on the distribution of Covid-19 vaccines in the country. With furniture company to entertainment firms already venturing into the business, we have now MyEG a company involved in road tax and foreign workers getting into an agreement with a Chinese pharmaceuticals company to distribute halal vaccine in the country.
MyEG will be working with Anhui Zhifei Longcom Biopharmaceutical to exclusively develop and distribute halal vaccines for a period of 3 years. Both companies have signed a Memorandum of Understanding, agreeing to cooperate in conducting Phase 3 clinical trials of Zhifei’s vaccine in Malaysia and in achieving compliance to Halal status requirements to secure Halal certification from the Department of Islamic Development Malaysia.
The commencement of Phase 3 trial will make the vaccine one of the first to undergo this final stage trial in Malaysia under the purview of the Ministry of Health. Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, mainly the production of vaccines for human use. Zhifei is presently one of five Chinese companies conducting Phase 3 clinical trials of their COVID-19 vaccines in various parts of the world.
Once ready, MYEG will manage the logistics and administrative aspects for COVID-19 testing and vaccination to ensure effective implementation. Having been involved with the Ministry of Health to develop and operate the MySafeTravel digital health pass system, the company is experienced on the government requirements and protocols in deploying services for the current health scare.